Editorial: Stem cell property
By Sacramento Bee,
Sacramento Bee
| 08. 29. 2005
Who will profit from stem cell investment?
Cast your mind back to September 2004. Hollywood actors, Nobel laureates and patient advocates were urging voters to approve a $3 billion bond package for stem cell research. To counter concerns that a cash-strapped state couldn't afford to loan $3 billion ($6 billion with interest), proponents commissioned a study to buttress their claim that Proposition 71 would produce an economic windfall.
The study, conducted by a Stanford University professor and a consulting firm, the Analysis Group Inc., concluded that Proposition 71 would save billions of dollars in health care costs and provide the state with $537 million to $1.1 billion in direct royalties from new stem cell therapies. Two months later, nearly 60 percent of voters approved the initiative.
Now return to the present. Legislators and public interest groups, excited about the potential of stem cell research, are insisting on licensing agreements that will ensure that California gets its promised benefits, either through royalties or discounted therapies. This is reasonable. Californians should expect something from a $3 billion investment that likely will make...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Ian Sample, The Guardian | 03.08.2024
Scientists are a step closer to making IVF eggs from patients’ skin cells after adapting the procedure that created Dolly the sheep, the first cloned mammal, more than two decades ago.
The work raises the prospect of older women being...
By Ramon Antonio Vargas, The Guardian | 02.28.2024
Doctors say a man in California who contracted blood cancer while living with HIV is in remission from both potentially fatal illnesses thanks to a treatment they are hailing as remarkable and encouraging.
Paul Edmonds is only the fifth-known person...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...